10x Genomics

TXG

Market cap $2.65B

10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology 10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.

Multi-phase initiative will generate single cell and spatial data from over 20,000 samples across leading immuno-oncology laboratories to map the immune landscape of cancer and drive the next generation of immunotherapies and vaccine discovery PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc.

PLEASANTON, Calif., Jan. 11, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to eluci.

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region PLEASANTON, Calif. and SYDNEY , Nov. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc.

PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, at 11:20 a.m.

10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.